Oral Dilşah, Örgüç İhsan Şebnem, Mavili Hanife Seda, Coşkun Teoman
Manisa Celal Bayar University Hafsa Sultan Hospital, Department of Radiology, Manisa, Türkiye.
Manisa Celal Bayar University Hafsa Sultan Hospital, Department of Pathology, Manisa, Türkiye.
Diagn Interv Radiol. 2025 Jul 21. doi: 10.4274/dir.2025.253352.
This study aimed to determine the performance of contrast-enhanced mammography (CEM) in evaluating suspicious calcifications not associated with a mass.
Patients with suspicious calcifications detected on CEM performed at our center between February 2021 and December 2023 were included in the study. Retrospectively, the morphology, distribution, and longest axis length of the calcifications were assessed on low-energy images, whereas contrast enhancement intensity, pattern, longest axis length, and enhancement curves were analyzed on recombined images. The pathological diagnosis, grade, Ki-67 index, and (if available) the longest lesion length in the surgical specimen were recorded. Using pathology as the gold standard, various CEM parameters were evaluated for their performance in assessing this group of calcifications. Primary and secondary analyses were performed based on combined low or no enhancement and no enhancement alone, respectively.
Our study includes 132 lesions in 114 patients,18 of whom had bilateral calcifications. Of the 132 lesions included in the study, 78 were benign, and 54 were malignant. Sensitivity, specificity, positive predictive value, and negative predictive value were determined as follows: 72.2%, 62.8%, 57.3%, and 76% in low-energy images; 79.6%, 80.8%, 74.1%, and 85.1% in the primary analysis of recombined images; and 98.2%, 47.4%, 56.4%, and 97.4% in the secondary analysis. Contrast enhancement intensity was identified as a significant parameter influencing malignancy risk. A strong statistical correlation was observed between lesion length measurements in both low-energy and recombined images compared with pathology (r = 0.733 and r = 0.879, < 0.001 for both), with mean differences of -4.75 mm and +4.45 mm. No statistically significant relationship was found between contrast enhancement intensity and the distinction between invasive and carcinoma ( = 0.698) or the differentiation of ductal carcinoma grade ( = 0.336). A significant correlation was detected between pathology and dynamic contrast enhancement types adapted from magnetic resonance imaging (MRI) ( = 0.019). Although no statistically significant linear correlation was found between the Ki-67 index and contrast enhancement intensity, the value was close to significance ( = 0.057).
CEM demonstrates strong performance in the assessment of suspicious calcifications by combining the morphological and distributional features of digital mammography with enhancement characteristics similar to MRI.
The findings support that CEM exhibits effective performance in evaluating suspicious calcifications not associated with a mass and may have a potential role in routine clinical practice.
本研究旨在确定对比增强乳腺钼靶摄影(CEM)在评估与肿块无关的可疑钙化方面的性能。
纳入2021年2月至2023年12月在本中心进行CEM检查时发现可疑钙化的患者。回顾性地在低能量图像上评估钙化的形态、分布和最长轴长度,而在重组图像上分析对比增强强度、模式、最长轴长度和增强曲线。记录病理诊断、分级、Ki-67指数以及(如可用)手术标本中的最长病变长度。以病理为金标准,评估各种CEM参数在评估这组钙化方面的性能。分别基于低增强或无增强以及单独无增强进行一级和二级分析。
我们的研究包括114例患者的132个病变,其中18例有双侧钙化。在纳入研究的132个病变中,78个为良性,54个为恶性。低能量图像中的敏感性、特异性、阳性预测值和阴性预测值分别为:72.2%、62.8%、57.3%和76%;重组图像一级分析中的分别为:79.6%、80.8%、74.1%和85.1%;二级分析中的分别为:98.2%、47.4%、56.4%和97.4%。对比增强强度被确定为影响恶性风险的重要参数。与病理结果相比,低能量图像和重组图像中病变长度测量值之间存在强统计学相关性(r = 0.733和r = 0.879,两者均P < 0.001),平均差异分别为-4.75 mm和 +4.45 mm。对比增强强度与浸润性癌和导管原位癌的区分(P = 0.698)或导管原位癌分级的分化(P = 0.336)之间未发现统计学上的显著关系。病理结果与从磁共振成像(MRI)改编的动态对比增强类型之间检测到显著相关性(P = 0.019)。尽管在Ki-67指数与对比增强强度之间未发现统计学上的显著线性相关性,但P值接近显著性(P = 0.057)。
通过将数字乳腺钼靶摄影的形态和分布特征与类似MRI的增强特征相结合,CEM在评估可疑钙化方面表现出强大性能。
这些发现支持CEM在评估与肿块无关的可疑钙化方面表现出有效性能,并且可能在常规临床实践中具有潜在作用。